(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
Quarter results tomorrow
(bmo 2024-05-20)
Expected move: +/- 8.33%
-1.70% $ 1.730
Live Chart Being Loaded With Signals
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...
Stats | |
---|---|
Dzisiejszy wolumen | 45 224.00 |
Średni wolumen | 64 693.00 |
Kapitalizacja rynkowa | 11.20M |
EPS | $0 ( 2024-03-29 ) |
Następna data zysków | ( $-0.790 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.480 |
ATR14 | $0.0300 (1.72%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Werner Milton H. | Buy | 45 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Buy | 90 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Sell | 5 834 | Stock Option (right to buy) |
2023-06-30 | Berman Dennis N | Buy | 6 667 | Stock Option (right to buy) |
2023-06-30 | Dion Gisele | Buy | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.37 |
Last 62 transactions |
Buy: 1 923 769 | Sell: 2 120 717 |
Wolumen Korelacja
Inhibikase Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inhibikase Therapeutics, Korelacja - Waluta/Towar
Inhibikase Therapeutics, Finanse
Annual | 2023 |
Przychody: | $260 500 |
Zysk brutto: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2023 |
Przychody: | $260 500 |
Zysk brutto: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2022 |
Przychody: | $123 440 |
Zysk brutto: | $116 717 (94.55 %) |
EPS: | $-4.26 |
FY | 2021 |
Przychody: | $3.10M |
Zysk brutto: | $3.10M (100.00 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Inhibikase Therapeutics,
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej